Dipeptidyl peptidase-4 (DPP-4) inhibitors have exceptional safety and efficacy characteristics and are commonly employed to treat patients suffering from chronic kidney disease and diabetes mellitus as a comorbidity. The gene discussed is DPP4; the disease is diabetes mellitus.